Anti-tumor activities of lung cancer dendritic cell vaccine modified by mutant Ki-ras gene in vitro.

Author: Jingrui YU ¹ ; Yanrong LU ; Wen ZHU ; Yanping WANG ; Xiaohe CHEN ; Cheng YI ; Deyun LUO ; Michael T LOTZE ; Qinghua ZHOU
Author Information

1. Key Laboratory of Lung Cancer Molecular Biology of Sichuan Province and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R.China.
Publication Type:Journal Article
From: Chinese Journal of Lung Cancer 2004;7(2):104-107
CountryChina
Language:Chinese
Abstract:
BACKGROUNDTo construct a DC-Ad-Ki-ras(V12) vaccine and investigate the anti-tumor activities of lung cancer dendritic cell vaccine modified by mutant Ki-ras gene in vitro.
METHODSKi-ras(V12) cDNA was transfected into cultured bone marrow-derived DC with the recombinant adenovirus [(Ad-Ki-ras(V12)] containing human mutant Ki-ras gene. Anti-tumor activity of the vaccine was studied in vitro by flow cytometry, PCR, MLR and cytotoxicity assay.
RESULTS(1) The DC vaccine was confirmed not only to express Ki-ras(V12) gene, but also to remarkably stimulate lymphocyte proliferation and improve CTL activity. (2) The DC vaccine modified by mutant Ki-ras gene could induce specifical CTL activity of immunized mice against Lewis lung carcinoma that could express Ki-ras(V12) gene, but not to B16.
CONCLUSIONSThe DC vaccine modified by mutant Ki-ras gene can induce obvious anti-tumor activities against Lewis lung carcinoma that can express Ki-ras(V12) gene.